Immune Support Stack

Thymosin Alpha-1 and LL-37 work synergistically by targeting different branches of the immune system. Thymosin Alpha-1 primarily influences adaptive immunity through T-cell modulation, whilst LL-37 strengthens innate immune defences through antimicrobial peptide activity.

Thymosin Alpha-1 enhances the differentiation and maturation of T-cells in the thymus, promoting a balanced Th1/Th2 response. Studies demonstrate its ability to increase CD4+ and CD8+ T-cell counts, improve natural killer cell activity, and enhance interferon-gamma production. This creates a more robust adaptive immune response capable of recognising and eliminating specific threats.

LL-37, the only human cathelicidin, provides the first line of defence through direct antimicrobial action against bacteria, viruses, and fungi. Beyond its antimicrobial properties, LL-37 supports immune cell chemotaxis, promotes wound healing, and helps regulate inflammatory responses. Research suggests it may also enhance vitamin D signalling, further supporting immune function.

The complementary nature of these peptides creates multiple immune enhancement pathways. Whilst Thymosin Alpha-1 builds long-term adaptive immunity, LL-37 provides immediate protection and supports tissue repair. This dual approach may be particularly beneficial during periods of increased pathogen exposure or immune system stress.

Both peptides demonstrate immunomodulatory rather than purely stimulatory effects, potentially reducing the risk of immune system overactivation. This makes the combination suitable for maintaining immune balance rather than simply boosting immune activity.

Thymosin Alpha-1 Protocol:

• Dose: 1.6mg twice weekly (Monday/Thursday)
• Administration: Subcutaneous injection, alternating sites
• Timing: Morning on empty stomach
• Cycle: 8-12 weeks, followed by 4-week break

LL-37 Protocol:

• Dose: 200-300mcg daily
• Administration: Subcutaneous injection
• Timing: Evening, 2 hours after dinner
• Cycle: 4-6 weeks on, 2 weeks off

Preparation and Administration: Both peptides require reconstitution with bacteriostatic water. Use our reconstitution guide for proper mixing techniques. Thymosin Alpha-1 typically comes as 1.6mg vials, whilst LL-37 is commonly available in 2mg vials.

Injection Sites: Rotate between abdomen, thigh, and upper arm to prevent tissue irritation. Use 31-gauge insulin needles for comfort. Clean injection sites with alcohol and allow to dry completely.

Storage: Reconstituted peptides must be refrigerated at 2-8°C. Thymosin Alpha-1 remains stable for 30 days post-reconstitution, whilst LL-37 should be used within 14 days.

Timing Considerations: Separate injections by at least 4 hours if administering both on the same day. Consider taking Thymosin Alpha-1 on weekdays and LL-37 daily to optimise compliance.

Cycle Management: Monitor immune markers through blood work if possible. Some users prefer continuous low-dose protocols rather than cycling, particularly during high-risk periods.

Week 1-2: Initial adaptation period with minimal noticeable effects. Some users report improved sleep quality and slightly increased energy levels. The immune system begins responding to peptide signalling.

Week 3-4: More apparent benefits emerge. Users commonly report feeling more resilient to minor illnesses, faster recovery from exercise, and improved overall vitality. Sleep quality typically continues improving.

Month 2: Enhanced immune resilience becomes more pronounced. Research participants often show improved immune cell markers. Users report fewer minor infections and faster resolution of any illness symptoms that do occur.

Month 3 and Beyond: Optimal benefits typically manifest by this point. Studies suggest sustained improvements in T-cell function and antimicrobial peptide activity. Users often report maintaining better health during traditionally challenging periods like winter months.

Response varies significantly between individuals. Those with compromised immune function may notice benefits earlier, whilst healthy individuals might experience subtler improvements. Consistency with dosing protocols appears crucial for optimal outcomes.

Common Side Effects: Both peptides are generally well-tolerated. Injection site reactions including redness, swelling, or mild discomfort occur occasionally. These typically resolve within 24-48 hours.

Thymosin Alpha-1 Specific: Rare reports of fatigue or mild flu-like symptoms during initial weeks. Some users experience temporary changes in lymph node sensitivity.

LL-37 Specific: Occasional reports of mild nausea or digestive changes. Given its antimicrobial properties, some users experience temporary changes in gut microbiome.

Contraindications: Avoid if pregnant, breastfeeding, or planning pregnancy. Those with autoimmune conditions should consult healthcare providers before use. Not recommended for individuals under 18 or those with active infections requiring medical treatment.

UK Legal Considerations: Both peptides fall under UK medicines regulations. Review our UK peptide legality guide for current regulatory status and purchasing guidelines.

Drug Interactions: Limited interaction data exists. Exercise caution when combining with immunosuppressive medications or other immune-modulating compounds. Always inform healthcare providers about peptide use before medical procedures.